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Circulating tumor DNA (ctDNA) is short, typically <167 base pairs long DNA fragments1 in body fluids, 
for example, serum and plasma fractions of bloodstream. While mechanisms for ctDNA release are 
currently poorly understood, a number of articles report good congruence between the mutations 
and copy-number alterations (75%-100%)2–4 identified from ctDNA and representative tissue 
biopsy. As ctDNA sampling is minimally invasive, ctDNA reflects better cancer heterogeneity in a 
patient than a tumor biopsy5, and in solid tumor cancers often the only option to query genomic 
landscape of relapsed disease and metastases, it has been welcomed as a basis for precision 
oncology approaches. 
 
Utility of ctDNA has been well documented in early detection of cancer4, 6, prognosis7–9, and 
treatment monitoring10, 11. In CancerSEEK study, 43% of stage I cancers were detected from ctDNA4 
and in general, 70% of cancers were detectable from ctDNA. CtDNA has also been used to detect 
possible residual disease after primary treatment to identify patients with poor prognosis8. Overall, 
treatment response monitoring through ctDNA allele frequencies is widely adaptable11. However, 
evidence for the use of ctDNA in guiding treatment decisions currently is scarcer12. In this editorial 
we focus on the use of ctDNA in precision oncology in guiding treatments of patients with solid 
tumor cancers. 
 
ctDNA is used in guiding treatments for non-small cell lung cancer, where EGFR tyrosine kinase 
inhibitors (TIKs) are given based on EGFR mutations13. Currently, the lung cancer ctDNA test is the 
only FDA approved test for ctDNA-guided treatment. CtDNA is also used for colorectal cancer to 
target anti-EGFR treatments to specific patients through EGFR and KRAS mutations12. In other 
cancers, ctDNA has been used to guide treatment based on mutations in multiple different genes 
for example in gastric cancer14, 15, colorectal cancer16 and pancancer settings 17–19 with positive 
impact on survival.  
 
We recently published a paper on the use of ctDNA in management of high-grade serous ovarian 
cancer (HGSOC)2. HGSOC is the most frequent and lethal subtype of epithelial ovarian cancer with 
five-year survival of only 43%. Most patients respond to primary therapy, consisting platinum-based 
chemotherapy and debulking surgery, but eventually relapse with limited treatment options. All 
HGSOC patients have TP53 driver mutation, and tumors are characterized by large molecular 
heterogeneity and abundant copy-number changes. We used targeted sequencing panel of over 
600 cancer-related genes and longitudinal sampling to genetically profile 12 patients. In seven 
patients, actionable targetable mutations and copy-number alterations were identified. For one of 
them, treatment was changed to include trastuzumab based on the revealed ERBB2 amplification, 
which resulted in a rapid and dramatic clinical response.  
 
In ovarian cancer, treatment response and detection of relapse are commonly tracked through CA-
125 through blood. Even with available detection method, ctDNA has shown to detect treatment 
response more sensitively and relapse earlier than CA-12520, 21. The tumor burden analyses are 
based on truncal TP53 mutation allelic frequencies in plasma. The early detection of relapse in 
combination with timely molecular profiling would allow to treat ovarian cancer patients more 
efficiently. 
 
The main reasons for a relative small number of cases where ctDNA has been used in guiding 
treatment decisions are as follows. Firstly, the quality of bioinformatics pipelines for ctDNA data 
analysis has been variable and often poorly documented. Secondly, low amount of ctDNA makes it 
difficult to obtain enough information and differentiate true signal from noise22. Thirdly, timeframe 
to provide information from ctDNA has been too long to provide timely information to treat patients 
at the clinic. Lastly, focus has been only on single mutations. It has worked in some cancers, like 
EGFR mutant lung cancer, but suffers from the heterogeneity between and within patients or 
possible reversion events.  
 
All the above issues are solvable. Bioinformatics community has responded to the need for open,  
tailored ctDNA pipelines and several pipelines have been published1, 2. These new public pipelines 
for variant calling and filtering enable development of state-of-the-art methods and enable reliable 
comparisons between studies which may enlighten some of the differences detected earlier23. 
Better protocols for data analysis ensure maximum sensitivity and specificity from the provided 
sequencing data. Simultaneous development of more sensitive sequencing techniques8 enable the 
detection of lower amounts of ctDNA. Especially the sequencing of early stage cancers and post-
surgical minimal residual disease depend on detection of extremely low amounts of ctDNA. New 
detection techniques have significantly improved the detection limits and there are protocols 
suitable for detection of low amount of ctDNA in residual disease, as low as 0.0003 allele fractions8. 
The detection limits for larger panels and other than patient-specific mutations are still higher but 
ongoing efforts are made to overcome the issue also in these assays. Maturation of the protocols 
has also improved the timeline from sample extraction to passing of clinically relevant information 
back into the clinics.  
 
Many ctDNA assays provide information on individual mutations, copy-number alterations, or DNA 
methylations to guide treatment. In studies, where ctDNA-guided matched treatment has been 
used, not all patients are identified with targetable mutations. A partial explanation is the low 
number of covered genes and/or low sensitivity. Larger panels exist to detect more rigorous 
molecular profile and further information on other genetic variation altering the mutation-related 
response are already being used18. When knowledge on molecular variants affecting drug response 
continue to accumulate, it will be possible to identify more significant, clinically relevant alterations 
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